



FEB 2 7 2009

# Great Lakes Orthodontics, LTD.

An Employee Owned Company

Our Vision "Delight our customers. Respect and help our co-workers."  $510(k)~{
m SUMMARY}$ 

CONTACT PERSON: Mark Lauren Great Lakes' Orthodontics

mlauren@greatlakesortho.com 800-828-7626

DATE PREPARED: November 20, 2008

TRADE OR PROPRIETARY NAME: Biocryl X

COMMON NAME: Radiopaque dental acrylic, cold-cure acrylic

CLASSIFICATION NAME: Denture relining, repairing, or rebasing (872.3760)

PRODUCT CODE: EBI

PREDICATE DEVICE: Biocryl<sup>TM</sup>

Great Lakes Orthodontics

200 Cooper Avenue Tonawanda, NY 14150

## DEVICE DESCRIPTION

Biocryl X is a radiopaque, auto-polymerizing powder/liquid dental acrylic system.

#### INTENDED USE

Biocryl X is intended for the laboratory fabrication of radiographic templates to be worn by a patient during x-ray imaging.

#### TECHNOLOGICAL CHARACTERISTICS COMPARED TO PREDICATE DEVICE

Biocryl X was evaluated as follows:

Mechanical properties, Hardness, Exotherm, Water absorption and extractables, and Working times.

Biocryl X was also evaluated as follows:

Agar Diffusion Assay

non-cytotoxic

Mucous Membrane Irritation

non-irritant

Klingman Maximization Test

non-sensitizer

We conclude that the similarity in comparison between Biocryl X and the predicate device, as well as the performance data and biocompatibility results, support the safety and effectiveness of Biocryl X for the indicated uses.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 2 7 2009

Mr. Mark Lauren Great Lakes Orthodontics, Limited 200 Cooper Avenue P.O. Box 5111 Tonawanda, New York 14151

Re: K083479

Trade/Device Name: Biocryl X

Regulation Number: 21 CFR 872.3760

Regulation Name: Denture Relining, Repairing, or Rebasing Resin

Regulatory Class: II Product Code: EBI

Dated: December 19, 2008 Received: December 19, 2008

## Dear Mr. Lauren:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Ginette Y. Michaud, M.D.

Acting Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# Indications for Use

	Device Name: Biocryl X			
	Indications For Use:		•	
		indicated for the rn during x-ray i	fabrication of dental radiograp maging.	)hi
. •				
	Prescription Use X (Part 21 CFR 801 Subpart D)	_ AND/OR	Over-The-Counter Use (21 CFR 801 Subpart C)	
	(PLEASE DO NOT WRITE NEEDED)	BELOW THIS LINI	E-CONTINUE ON ANOTHER PAGI	ΕI
). 2.	Concurrence of	CDRH Office of	Device Evaluation (ODE)	
** B .	gn-Off)	ODINII, OINCO	Device Evaluation (ODE)	